Popular terms

G Proteins topics
G Proteins
Antibodies
Immunoglobulin
Metalloprotein
Chemotherapeutic Agent
Kinase Inhibitor
Tetrapeptide
Apoptosis Protein
Topoisomerase
Peptidomimetic
Fractionation
Medical Treatment
Chromatograph
Encapsulation
Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Proteins patents



      

This page is updated frequently with new G Proteins-related patent applications.




Date/App# patent app List of recent G Proteins-related patents
02/04/16
20160032014 
 Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 patent thumbnailHuman antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr and having increased ph sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind pcsk9 and have increased ph sensitivity, improved binding affinity and/or increased in vivos half life.
Amgen Inc.


02/04/16
20160032000 
 Blood-brain-barrier dual variable domain immunoglobulins and uses thereof patent thumbnailBlood-brain-barrier dual variable domain immunoglobulins and uses thereof
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


02/04/16
20160031999 
 Il-11r binding proteins patent thumbnailIl-11r binding proteins
The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (il-11) receptor alpha (il-11rα) and uses thereof, e.g., in therapy.. .
45 Poplar Road


02/04/16
20160031997 
 Methods and compositions relating to anti-ccr7 antigen binding proteins patent thumbnailMethods and compositions relating to anti-ccr7 antigen binding proteins
The present invention provides compositions and methods relating to antigen binding proteins against ccr7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.. .
Amgen Inc.


02/04/16
20160031986 
 Therapeutic dll4 binding proteins patent thumbnailTherapeutic dll4 binding proteins
Dll4 binding proteins are described herein, including antibodies, cdr-grafted antibodies, humanized antibodies, and dll4 binding fragments thereof, proteins that bind dll4 with high affinity, and dll4 binding proteins that neutralize dll4 and/or vegf activity. The dll4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis..
Abbvie Inc.


02/04/16
20160031985 
 Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use patent thumbnailCharge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
The disclosure relates to charge-engineered antibodies and penetration-enhanced targeted proteins and their uses for therapeutic treatment or therapeutics delivery.. .
Permeon Biologics, Inc.


02/04/16
20160031832 
 Quinazolinone antibiotics patent thumbnailQuinazolinone antibiotics
A new class of antibiotics effective against methicillin-resistant staphylococcus aureus (mrsa) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (pbp) 2a.
University Of Notre Dame Du Lac


02/04/16
20160030584 
 Method for preserving and stabilising proteins, which can be used for industrial development of formulations of sanitary, pharmaceutical and cosmetic products patent thumbnailMethod for preserving and stabilising proteins, which can be used for industrial development of formulations of sanitary, pharmaceutical and cosmetic products
A method for preserving and stabilising proteins is disclosed which can be used for the industrial development of formulations of sanitary, pharmaceutical and cosmetic products, particularly cell growth factors and/or proteins such as epidermal growth factor (egf) and fibroblast growth factor (bfgf). The method includes a dispersion phase, under normal pressure and temperature conditions, in which the proteins are incorporated into an anhydrous medium formed by oily components that have hydrophilic residues and that guarantee interactions with the proteins, while maintaining the native conformation of the proteins, such components being grape seed oil, a base of different components and butylhydroxytoluene..
Sani-red, S.l.


01/28/16
20160025747 
 Use and treatment of di-amino acid repeat-containing proteins associated with als patent thumbnailUse and treatment of di-amino acid repeat-containing proteins associated with als
Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (als) or frontotemporal dementia (ftd). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein..
University Of Florida Research Foundation, Inc.


01/28/16
20160024558 
 Nucleic acid binding proteins and uses thereof patent thumbnailNucleic acid binding proteins and uses thereof
Compositions, systems and methods employing nucleic acid binding proteins for use in the regulation and/or modulation of nucleic acid based reactions, including transcription, translation, modification, digestion, and hybridization reactions. Such compositions are employed in controlling a variety of different reaction types involving nucleic acids..
10x Genomics, Inc.


01/28/16
20160024511 

Yeast promoters for protein expression


Isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are disclosed. More specifically, nucleic acids isolated from pichia pastoris having promoter activity and expression methods, host cells, expression vectors, and dna constructs of using the pichia pastoris promoters to produce different proteins and polypeptides are disclosed..
Biogrammatics, Inc.


01/28/16
20160024222 

Monoclonal antibodies against antithrombin b


This patent document relates to antibodies, antigen-binding antibody fragments (fabs), and other protein scaffolds, directed against human antithrombin β complexed with heparin and/or heparin-like structure (atβh). These atβh binding proteins can block the anti-coagulant activity of atβ to induce coagulation.
Timothy Myles


01/28/16
20160024196 

Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment


Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the sfrp5 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy..
Amgen Inc.


01/28/16
20160024172 

Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof


The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (rap) and compositions thereof, methods of generating such variants and methods of using such receptor-selective rap variant compositions for therapeutic purposes.. .
Raptor Pharmaceuticals Inc.


01/28/16
20160024161 

Novel binding proteins for pcsk9


The present disclosure relates to novel lipocalin muteins which bind to pcsk9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules..
Daiichi Sankyo Co., Ltd.


01/28/16
20160024096 

Methods and compositions for inhibition of bromodomain-containing proteins


The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.. .
Convergene Llc


01/21/16
20160017047 

Cd20-binding immunotoxins for inducing cellular internalization and methods using same


The present invention provides cd20-binding proteins that bind to and rapidly internalize cd20 antigens from a cell surface location to the interior of a cell. Cd20-binding proteins of the invention comprise a cd20 binding region and a shiga toxin effector region.
Molecular Templates, Inc.


01/21/16
20160017037 

Anti-lag-3 binding proteins


Antigen binding proteins that bind lymphocyte activation gene 3 (lag-3), and more particularly to antigen binding proteins that cause depletion of lag-3+ activated t cells.. .
Glaxosmithkline Intellectual Property Development Limited


01/21/16
20160015555 

Tissue crosslinking for treatment of snoring and obstructive sleep apnea


A method of treating snoring and/or osa in a subject in need of such treatment. The method includes crosslinking proteins of the subject's soft palate tissue or pharynx tissue.
Orthopeutcs. L.p.


01/07/16
20160004812 

Pharmacogenic therapies targeting the metal-ion transcriptional regulation machinery in bacteria


The subject invention pertains to methods of identifying compounds that bind to a binding pocket on metal ion binding proteins of arsr/smtb family and modulate their regulatory activity by increasing the propensity of the protein to remain in a conformationally trapped form such as the metal ion bound conformation or disulfide-linked conformation, dna bound conformation, or the apo-conformation. The invention provides methods of identifying such compounds using computer software programs.
University Of Florida Research Foundation, Incorporated


01/07/16
20160002625 

Cancer treatment


In certain embodiments, methods, compounds, and compositions for treating b-cell lymphoma or hepatocellular carcinoma by inhibiting expression of st at3 mrna or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate b-cell lymphoma or hepatocellular carcinoma.
Isis Pharmaceuticals Inc.


01/07/16
20160002623 

Genes expressed in mental illness and mood disorders


The present invention relates to a composition comprising a plurality of cdna molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar i disorder, bipolar ii disorder, unipolar disorder, schizophrenia, attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cdna molecules may be used in their entirety or in part as to diagnose, to stage, to treat, and/or to monitor the treatment of a subject with mental illness..
Psychnostics, Llc


01/07/16
20160002346 

Her1 antigen binding proteins binding to the beta-hairpin of her1


The invention relates to anti-her1 antigen binding proteins, e.g. Anti-her1 antibodies, that bind to the beta-hairpin of her1, methods for selecting these antigen binding proteins, their preparation and use as medicament..
Hoffmann-la Roche Inc.


01/07/16
20160002343 

Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases


Engineered agents or multivalent and multispecific binding proteins capable of penetrating the cells or tissue of the blood-brain barrier (bbb) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


01/07/16
20160002333 

Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


01/07/16
20160002326 

Compositions and methods for treating rheumatoid arthritis


The treatment of rheumatoid arthritis using engineered multivalent and multispecific binding proteins that target tnf and il-17 is provided.. .
Abbvie Inc.


01/07/16
20160002324 

Anti-ngf antibodies and their use


The present disclosure encompasses ngf binding proteins, specifically to antibodies that are chimeric, cdr grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting ngf and for inhibiting ngf activity, e.g., in a mammal subject suffering from a disorder in which ngf activity is detrimental..
Zoetis Belgium S.a.


01/07/16
20160002121 

Methods and compositions for radiohalogen protein labeling


Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests.
Genentech, Inc.


12/31/15
20150376286 

Human cgrp receptor binding proteins


Antigen binding proteins that bind to human cgrp receptor (cgrp r) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided.
Amgen Inc.


12/31/15
20150376246 

High affinity digoxigenin binding proteins


Isolated polypeptides with steroid binding activity and methods for their use as therapeutics and detection agents are disclosed herein.. .
University Of Washington Through Its Center For Commercialization


12/31/15
20150376229 

Tangential flow filtration based protein refolding methods


Provided herein are methods for refolding proteins that are denatured. Exemplary methods comprise solubilizing the denatured protein with a denaturing agent, e.g., a chaotropic agent, and renaturing the protein using a buffer exchanging system, e.g., tangential flow filtration (tff)..
Bristol-myers Squibb Company


12/31/15
20150374837 

Antibacterial agent for treating infectious diseases of bacterial origin


The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant tb which represents the ion nanostructured complex (insc) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as phe, ala, val, ala, leu, ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant tb; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (bafs or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. Insc has the formula [{(ln(mei3)+)y[me(lm)i]+x}(cl—)y+x+k] with m=30-300 kda..
"scientific Center Of Anti-infectious Drugs" Joint-stock Company


12/24/15
20150369711 

Fluorous affinity extraction for ionic liquid-based sample preparation


A method for removing an ionic liquid from an aqueous sample is provided. In some embodiments, the method includes: (a) combining an aqueous sample including an ionic liquid with an ion exchanger composition including an ion exchanger counterion to produce a solution including a fluorous salt of the ionic liquid, where at least one of the ionic liquid and the ion exchanger counterion is fluorinated; (b) contacting the solution with a fluorous affinity material, thereby removing fluorous salt from the solution and producing an aqueous eluate; and (c) collecting the aqueous eluate.
Agilent Technologies, Inc.


12/24/15
20150368333 

Tnf-alpha antigen-binding proteins


The present invention provides antigen binding proteins which bind specifically to tnf-alpha. For example novel variants of anti-tnf antibodies such as adalimumab which show increased binding to the fcrn receptor or increased half life compared to adalimumab.
Glaxosmithkline Intellectual Property Development Limited


12/24/15
20150368302 

Designed ankyrin repeat proteins binding to platelet-derived growth factor


New designed ankyrin repeat proteins with binding specificity for pdgf-bb are described, as well as nucleic acids encoding such pdgf binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.. .
Molecular Partners Ag


12/24/15
20150368299 

Amyloid-beta binding proteins


The present invention relates to amyloid-beta (aβ) binding proteins. Antibodies of the invention have high affinity to aβ(20-42) globulomer or any β form that comprises the globulomer epitope.
Abbvie Inc.


12/17/15
20150361420 

Methods for screening proteins using dna encoded chemical libraries as templates for enzyme catalysis


Disclosed are methods, compositions and devices for screening a protein library for proteins having a desired activity, such as capable of catalyzing the formation of a bond between two reactants. In an exemplary embodiments, a plurality of proteins are expressed in vitro from a plurality of nucleic acids, the plurality of proteins are exposed with two single stranded oligonucleotides having complementary sequences, each oligonucleotide having a reactant and a fluorophore, the fluorescence of the protein-reactant-oligonucleotide-fluorophore complexes is detected and the complexes showing detectable fluorescence energy transfer are isolated, thereby isolating proteins having the desired enzymatic activity..
Gen9, Inc.


12/17/15
20150361130 

Capture purification processes for proteins expressed in a non-mammalian system


Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed.
Amgen Inc.


12/17/15
20150360180 

Single-pass filtration systems and processes


The present invention provides, in various embodiments, hybrid single-pass tangential flow filtration assemblies, disposable single-pass tangential flow filtration assemblies, scalable single-pass tangential flow filtration assemblies and adaptable modular single-pass tangential flow filtration assemblies. In other embodiments, the invention relates to processes for recovering proteins from the surface of a filtration membrane in a single-pass tangential flow filtration assembly and for cleaning a tangential flow filtration assembly.
Emd Millipore Corporation


12/10/15
20150355173 

High-throughput methodology for identifying rna-protein interactions transcriptome-wide


Methods of identifying rna-protein interaction sites are provided. Systems for identifying rna-protein interaction sites are provided.
The Trustees Of The University Of Pennsylvania


12/10/15
20150353923 

Method for identifying rna segments bound by rna-binding proteins or ribonucleoprotein complexes


The present invention relates to a method for identifying a binding site on an rna transcript, wherein the binding site binds to one or more binding moieties. The method includes, among other things, introducing a photoreactive nucleoside into living cells wherein the living cells incorporate the photoreactive nucleoside into rna transcripts during transcription thereby producing modified rna transcripts; reverse transcribing the rna of isolated cross-linked segments thereby generating cdna transcripts with one mutation wherein the photoreactive nucleoside is transcribed to a mismatched deoxynucleoside; amplifying the cdna transcripts thereby generating amplicons; and analyzing the sequences of the amplicons aligned against the reference sequence so as to identify the binding site, wherein the sequences of each amplicon having a mutation resulting from the introduction of the photoreactive nucleoside is considered to be a valid amplicon comprising at least a portion of a binding site on the rna transcript..
Rockefeller University


12/10/15
20150353606 

Peptidomimetic compounds


The present invention relates to inhibitors of protein-protein interactions (ppi). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer.
Noliva Therapeutics Llc


12/10/15
20150351371 

Hybrid light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


12/03/15
20150346209 

Method of labeling sulfenic acid-containing proteins and peptides


A method of labeling a sulfenic acid (—soh) group of a cysteine residue in a protein or peptide, comprises contacting said protein or peptide with a beta-ketoester to covalently couple said beta-ketoester to said cysteine residue and form a beta-ketoester-labeled cysteine residue in said protein or peptide.. .
Wake Forest University Health Sciences


12/03/15
20150344590 

Dual specific binding proteins directed against il-1 and/or il-17


Engineered multivalent and multispecific binding proteins that bind il-1β and/or il-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


12/03/15
20150344583 

Bcma antigen binding proteins


The present invention relates to bcma (b-cell maturation antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to bcma antibody drug conjugates and uses thereof..
Amgen Inc.


12/03/15
20150344566 

Dual specific binding proteins directed against il-13 and/or il-17


Engineered multivalent and multispecific binding proteins that bind il-13 and/or il-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


12/03/15
20150344539 

Binding proteins inhibiting the vegf-a receptor interaction


The present invention relates to binding proteins specific for vegf-a, in particular to recombinant binding proteins comprising a binding domain, which inhibits vegf-axxx binding to vegfr-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity.
Molecular Partners Ag


12/03/15
20150344538 

Novel specific-binding proteins and uses thereof


The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of swiss prot q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of swiss prot q9npf7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of swiss prot q16552 and swiss prot q9npf7.
Pieris Ag


12/03/15
20150342973 

Antibiotic compositions and related screening methods


Moenomycin inhibits bacterial growth by clocking the transglycosylase activity of class a penicillin-binding proteins (pbps), which are key enzymes in bacterial cell wall synthesis. The binding affinities of moenomycin a with various truncated pbps were compared showing that the transmembrane domain is important for moenomycin binding.
Academia Sinica


11/26/15
20150338398 

Methods and kits for isolation and analysis of a chromatin region


The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.. .
Board Of Trustees Of The University Of Arkansas


11/26/15
20150337399 

Hiv-1 genotyping and coreceptor tropism assay


A method for detecting low frequency occurrence of one or more hiv sequence variants associated with drug resistance and hiv tropism includes generating a plurality of cdna species from a plurality of rna molecules in an hiv sample population, amplifying a plurality of first amplicons and second amplicons from the cdna species, wherein the first amplicons are amplified using first pairs of primers that amplify a hiv genomic region of the cdna species encoding the gag proteins p2, p7, p1 and p6, and the protease, reverse transcriptase, and integrase enzymes and the second amplicons are amplified using second pairs of primers that amplify a hiv genomic encoding region of the cdna species encoding the env-c2v3 region; determining the nucleic acid sequence compositions of the amplified first amplicons second amplicons; identifying variants in the determined sequence by comparing the determined nucleic sequence to a guide sequence; and correlating the determined variants with variants of hiv drug resistance and hiv tropism.. .
Case Western Reserve University


11/19/15
20150329633 

Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies


Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal.
Incube Labs, Llc


11/19/15
20150329631 

Pharmaceutical compositions and methods for fabrication of solid masses comprising tnf-inhibiting antibodies


Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal.
Incube Labs, Llc


11/19/15
20150329630 

Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins


Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal.
Incube Labs, Llc


11/19/15
20150329588 

Protein purification using displacement chromatography


Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step.
Abbvie, Inc.


11/19/15
20150329586 

Refolding proteins using a chemically controlled redox state


A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/l, or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox butler strength to achieve conditions under which efficient folding at concentrations of 2.0 g/l or higher is achieved and can be employed over a range of volumes, including commercial scale..
Amgen Inc.


11/19/15
20150328287 

Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins


Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal.
Incube Labs, Llc


11/19/15
20150327572 

Method for obtaining valuable products, in particular proteins, from a native mixture of materials


A method for obtaining proteins from native mixtures of materials is disclosed. In an embodiment, the method includes: a): providing a native mixture of materials from seeds having hard fragmentable hulls; b): comminuting the mixture of materials; c): dispersing the comminuted mixture of materials with water; d): adjusting a ph of the pulp of step c) to an alkaline range ph>9.5; e): adding a water-soluble organic solvent alcohol to the pulp; f): separating off a solids phase from the pulp, which has a predominant fraction of the hulls, to form a hull-free pulp; g): shifting the ph of the hull-free pulp from step f) to a ph range of ph=4.5 to ph=7.2; and h): separating the hull-free pulp of step g) into a plurality of phases, wherein one of the plurality of phases is a protein concentrate phase..
Gea Mechanical Equipment Gmbh


11/12/15
20150323544 

Drug discovery and protein-protein interaction assay using fluorescent protein exchange


A novel assay for determining a molecular process using a fluorescent protein exchange assay, and a composition for use thereof, are provided. The assay provides first and second signalling proteins and an exchange protein, wherein the exchange protein interacts with the first signalling protein to form a complex, then introducing the second signalling protein, wherein in response to the molecular process, the exchange protein dissociates from the first protein and associates with the second protein.
The Governors Of The University Of Alberta


11/12/15
20150323542 

Fluorescent molecular probes for use in assays that measure test compound competitive binding with sam-utilizing proteins


Assay methods may generally comprise forming homogeneous assay mixtures comprising target sam-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring fp or tr-fret signal emitted in order to determine a measure of test compound-sam-utilizing protein binding. Assay mixtures comprise a sam-utilizing protein, and a fluorescent detection analyte that binds with the sam-utilizing protein in the absence of test compound.
The Regents Of The University Of Michigan


11/12/15
20150322472 

Reducing template independent primer extension and threshold time for loop mediated isothermal amplification


Compositions and methods are provided for loop mediated isothermal amplification in which single stranded binding proteins are shown to protect primers from non-specific extension and to stimulate the rate of threshold amplification.. .
New England Biolabs, Inc.


11/12/15
20150322423 

Protein alignment method


A method for aligning proteins is provided. The method for aligning the proteins (20 and 32) is capable of aligning proteins (20 and 32) on the substrate (10) comprising carbon.
Japan International Research Center For Agricultural Sciences


11/12/15
20150322154 

Hla-restricted, peptide-specific binding proteins


Antigen binding proteins with tcr-like paratopes, that is, with an antigen binding region specific for an hla-a2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv fragments.
Memorial Sloan Kettering Cancer Center


11/12/15
20150322107 

Fluorescent molecular probes for use in assays that measure test compound competitive binding with sam-utilizing proteins


Assay methods may generally comprise forming homogeneous assay mixtures comprising target sam-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring fp or tr-fret signal emitted in order to determine a measure of test compound-sam-utilizing protein binding. Assay mixtures comprise a sam-utilizing protein, and a fluorescent detection analyte that binds with the sam-utilizing protein in the absence of test compound.
The Regents Of The University Of Michigan


11/12/15
20150320846 

Methods of treatment using alpha-1-antitrypsin compositions


A streamlined method for purifying alpha-1-antitrypsin (aat) from an aat-containing protein mixture, such as coh fraction iv precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect aat.
Csl Behring L.l.c.


11/12/15
20150320023 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


11/05/15
20150315650 

Cc2d2a gene mutations associated with joubert syndrome and diagnostic methods for identifying the same


The present invention provides a method of screening a subject for mutations in the cc2d2a gene that are associated with joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with joubert syndrome including proteins that includes an amino acid sequence that terminates in dheggsgmes (seq id no: 1).
Centre For Addiction And Mental Health


11/05/15
20150315556 

Fusion molecules of rationally-designed dna-binding proteins and effector domains


Targeted transcriptional effectors (transcription activators and transcription repressors) derived from meganucleases are described. Also described are nucleic acids encoding same, and methods of using same to regulate gene expression.
Duke University


11/05/15
20150315283 

Dual variable domain immunoglobulins and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


11/05/15
20150315249 

Crosslinked thermoset resins and methods thereof


The present invention relates to a method of making a crosslinked thermoset resin. One embodiment of this method comprises: (i) separating a plant-derived flour mixture into a protein fraction comprising proteins and a carbohydrate fraction comprising carbohydrates; (ii) subjecting the carbohydrate fraction to an oxidizing agent to yield oxidized carbohydrates comprising aldehyde functional groups or both aldehyde functional groups and carboxyl functional groups; and (iii) reacting the oxidized carbohydrates with the protein fraction under conditions effective to crosslink the proteins, thereby yielding a crosslinked thermoset resin.
Cornell University


11/05/15
20150315232 

Refolding proteins using a chemically controlled redox state


A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/l or higher is disclosed. The method comprises identifying foe thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/l or higher is achieved and can be employed over a range of volumes, including commercial scale..
Amgen Inc.


11/05/15
20150313193 

Common light chain mouse


A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc.


10/29/15
20150309053 

Test method and test kit for psychiatric ailments


A novel test method for testing for the presence or absence of a predisposition to autistic spectrum disorder or the presence or absence of development of autistic spectrum disorder is provided. The test method includes a test step of determining an amount of at least one of the fatty acid binding proteins fabp3, fabp4, fabp5, and fabp7 in a sample prepared from the living body of a human or determining an expression level of at least one of the fabp3, fabp4, fabp5, and fabp7 genes in the sample..
National University Corporation Hamamatsu University School Of Medicine


10/29/15
20150307909 

Methods for enhancing the degradation of cellulosic material with chitin binding proteins


The present invention relates to methods for degrading or converting a cellulosic material and for producing substances from the cellulosic material.. .
Novozymes, Inc.


10/29/15
20150307899 

Baculovirus system for expressing proteins forming virus-like particles


The present invention may be included in the field of biotechnology and it covers the improved production of recombinant proteins in insect cells or insect larvae as biofactories by a novel expression cassette. This expression cassette comprises nucleic acid sequences such as promoters, homologous regions (hr) as enhancers, and sequences encoding transcriptional regulators, for example, the baculovirus ac-ie-01 cdna, or any combination thereof, which are able to increase the quality and production efficiency of the recombinant proteins.
Alternative Gene Expression S.l.


10/29/15
20150307627 

Single-domain antigen-binding proteins that bind mammalian igg


The present application relates to antigen-binding proteins that are capable of binding to mammalian igg. The frame-work regions of the antigen-binding proteins of the application preferably correspond to those of antibodies naturally that are devoid of light chains as may e.g.
Bac Ip B.v.


10/29/15
20150307625 

Monoclonal antibodies against activated protein c (apc)


Provided herein are antibodies, antigen-binding antibody fragments (fabs), and other protein scaffolds, directed against human activated protein c (apc) with minimal binding to its zymogen protein c (pc). Moreover, these apc binding proteins could potentially block the anti-coagulant activity of apc to induce coagulation.
Bayer Healthcare Llc


10/29/15
20150307560 

Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof


The present invention relates to compositions and methods for displaying proteins and polypeptides on the surface of cells and cellular vesicles. Methods and compositions for drug and vaccine delivery using cell surface display systems of the present invention are also disclosed..
Cornell Research Foundation, Inc.


10/29/15
20150307547 

Egg white processing


This disclosure relates to inexpensive and efficient methods of preparing egg white (e.g., obtained from eggs laid by transgenic chickens) for bulk chromatographic isolation of proteins (e.g., recombinant proteins) from the egg white, as well as methods of filtering acidified egg white and methods of isolating proteins from the egg white.. .
Synageva Biopharma Corp.


10/29/15
20150306248 

Chimeric vsv-g proteins as nucleic acid transfer vehicles


The design and generation of a number of chimeric vsv-g (or vsv-g variants) proteins are used as transfer vehicles to enhance delivery of nucleic acids like plasmid dna, single and double stranded dna and rna, and antisense oligonucleotides into human and animal cells. These chimeric vsv-g protein-nucleic acid transfer vehicles have widespread applications to deliver nucleic acids for exon skipping and gene delivery for gene replacement in human and animals..

10/22/15
20150301049 

Method for diagnosing and treating kidney injury or disease


The protein kinase c and casein kinase 2 substrate in neurons (pacsin) is a subfamily of membrane-binding proteins, participates in vesicle trafficking and cytoskeleton organization. Pacsin 2 expression is significantly upregulated during the repair phase of post ischemia-reperfusion injured (iri) kidneys, especially on the apical brush border of proximal tubules, which experienced massive damage.
The Brigham And Women's Hospital, Inc.


10/22/15
20150299702 

Circular rna for inhibition of microrna


The present invention relates to inhibition of micrornas (mirna), other types of rna and rna-binding proteins. In particular the present invention relates to nucleic acid sequences that are circular and allow inhibition of the interactions between micrornas and their rna target and being resistant to degradation by exonucleases.
Aarhus Universitet


10/22/15
20150299637 

Apparatus for automatically preparing cell-free proteins and preparing proteins using same


An automated cell-free protein production system comprises: a protein expression reaction unit comprising a reaction vessel that includes a plurality of dialysis tubes, each including a dialysis membrane and being open at its top; a reaction temperature control unit configured to heat or cool the reaction vessel; a pipette array comprising a plurality of pipettes and configured to suck or discharge solutions using the pipettes; a pipette array moving unit configured to move the pipette array in an upward and downward direction, a forward and backward direction or a left and right direction so as to move solutions; a protein purification unit including a magnetic field application device; and a multi-well plate mounting unit having mounted therein a multi-well plate kit configured to supply solutions that are used for protein production.. .
Bioneer Corporation


10/22/15
20150299265 

Binding proteins comprising at least two repeat domains against her2


The present invention relates to a recombinant binding protein comprising at least a first and a second repeat domain, wherein each of said two repeat domains binds the extracellular region of her2 and wherein said repeat domains are covalently linked.. .
Molecular Partners Ag


10/22/15
20150299238 

Synthesis and use of prodrug complexes of cobalt in polymer therapeutics


Degradable compounds that can be controlled to degrade and can be used for delivery of a cargo component. Cobalt (iii) complexes have been exploited as vehicles for molecular complexes.
The University Of North Texas


10/22/15
20150297697 

Cancer-associated antigen related applications


The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates.
Viventia Bio Inc.


10/22/15
20150297677 

Compositions and methods for inhibiting viral entry


The invention provides methods, compositions, and kits featuring agents that inhibit viral entry mediated by t-cell immunoglobulin and mucin-domain containing proteins (tim proteins) and other phosphatidylserine receptors.. .
Children Medical Center Corporation


10/15/15
20150293118 

Cross-reactive determinants and methods for their identification


Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive h. Parasuis proteins.

10/15/15
20150291966 

Inducible dna binding proteins and genome perturbation tools and applications thereof


The present invention generally relates to methods and compositions used for the spatial and temporal control of gene expression that may use inducible transcriptional effectors. The invention particularly relates to inducible methods of altering or perturbing expression of a genomic locus of interest in a cell wherein the genomic locus may be contacted with a non-naturally occurring or engineered composition comprising a deoxyribonucleic acid (dna) binding polypeptide..

10/15/15
20150291946 

Methods and vectors for generating asialylated immunoglobulins


The properties of an fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the fc region by transfecting the cell line expressing the fc-containing protein with a vector sequence encoding a sialidase. The modified fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the fcγri, fcγriia, and fcγriiia receptors, adcc activity, macrophage or monocyte activation, serum half-life, and avidity..

10/15/15
20150291701 

Methods for treating disorders associated with human signal peptide-containing molecules


The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.

10/15/15
20150290009 

Methods for making conjugates from disulfide-containing proteins


A weight loss device (1, 100) comprising at least one peripheral plate (10, 20, 110, 120) that can be fixed to at least one portion of an upper dental arch (2) or lower dental arch (3) by fixing means, in a fixing configuration. The peripheral plate (10, 20, 110, 120) supports, by way of supporting means (40, 140), at least one central plate (30, 130), which is adapted, in the fixing configuration, to rest against the palate (4) or the floor of the mouth (5) in order to limit the movements of the tongue (7) inside the mouth (6)..

10/15/15
20150289489 

Non-human animals that make single domain binding proteins


Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises (a) a deletion in an immunoglobulin constant region ch1 gene (optionally a deletion in a hinge region) of a heavy chain constant region gene sequence, and (b) replacement of one or all endogenous vh, dh and jh gene segments with at least one unrearranged light chain variable (vl) gene segment and at least one unrearranged light chain joining (jl) gene segment capable of recombining to form a rearranged light chain variable region (vl/jl) nucleotide sequence operably linked to the heavy chain constant region gene sequence comprising a deletion in the ch1 gene and/or insertion of a genetically engineered single rearranged light chain, wherein the mouse is capable of expressing a functional igm, single domain antigen binding proteins, e.g., vl-single domain binding proteins, and a genetically engineered rearranged light chain.. .

10/08/15
20150284759 

Method for producing d-allose


Provided herein is an enzyme protein produced by a highly safe microorganism and having the activity to isomerize d-psicose to d-allose. The protein is any of the following proteins (a) to (c) with the activity to isomerize d-psicose to d-allose.

10/08/15
20150284478 

Tethering cysteine residues using cyclic disulfides


Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including sod1 and dj-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker.

10/08/15
20150284471 

Human lcat antigen binding proteins and their use in therapy


Antigen binding proteins that activate lcat are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.

10/08/15
20150284452 

Antimicrobial compositions


The present invention relates antimicrobial compositions, and in particular to antigen binding proteins comprising one or more domains that provide antimicrobial activity.. .

10/08/15
20150283203 

Method for treating prostatitis utilizing pore-forming protein proaerolysin


The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins..

10/01/15
20150276755 

Methods for determining resistance against molecules targeting proteins


The present disclosure provides a method of determining resistance of a biological molecule to inhibition of its interaction with a target molecule by an inhibitor of the biological molecule, the method comprising the steps of: a) co-compartmentalizing a gene encoding the biological molecule with the target molecule, or a gene encoding the biological molecule with a gene encoding the target molecule into an aqueous droplet disposed within a water-in-oil emulsion, and b) assaying for a complex comprising the biological molecule and the target molecule upon expression of the gene encoding the biological molecule and the gene encoding the target molecule, wherein detection of the complex in the presence of the inhibitor indicates that the biological molecule is resistant to inhibition of its interaction with the target molecule by the inhibitor. Also provided are mutated hdm2 ubiquitin ligase polypeptides exhibiting resistance to nutlin inhibition of p53 binding..
Agency For Science, Technology And Research




G Proteins topics: G Proteins, Antibodies, Immunoglobulin, Metalloprotein, Chemotherapeutic Agent, Kinase Inhibitor, Tetrapeptide, Apoptosis Protein, Topoisomerase, Peptidomimetic, Fractionation, Medical Treatment, Chromatograph, Encapsulation, Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.8438

4655

2 - 1 - 101